Do "nucleic acid" into an industry, Shanghai Fengxian really did this?

Last weekend, the news of "Shanghai Nuclear acid Industrial Park recently started" was quickly spread in the circle of friends.

According to reports, Shanghai's first nucleic acid industrial park will officially start in the Hangzhou Bay Economic and Technological Development Zone in Fengxian in mid -July to create a "Oriental Meigu · Life Credit" nucleic acid industry ecosystem. The industrial park covers an area of ​​3 square kilometers, and it will build the first place and the pioneering area of ​​the 720 acres of nucleic acid industry in advance.

The word "nucleic acid" is now known for all people, and many cities also require "normalization" of nucleic acids. The jokes of "making nucleic acid detection into an industry" often appear. Unexpectedly, Shanghai Fengxian really did this?

On the morning of July 11, the official public account of the Press Office of the People's Government of Fengxian District, Shanghai, specially issued a document to clarify the relevant rumors.

The article said that the nucleic acid industrial park is a 'life merit industry', mainly based on RNA development of various vaccines and drugs. This is the future direction of the biomedical industry, which has nothing to do with the current Shanghai epidemic.

This nucleic acid is non -nucleic acid

The "nucleic acid industrial park" in Shanghai is located in the Shanghai Hangzhou Bay Economic and Technological Development Zone, and it is administrative in Fengxian District.

In the past two years, the test of new crown nucleic acid has become the main business of many companies. Jinyu Medicine's 2021 annual report shows that last year Jinshu Medical revenue was 11.943 billion yuan, of which nucleic acid tests contributed 4.456 billion yuan.

According to the macro research team of Huachen Securities, China has paid 300 billion yuan for nucleic acid testing in the past two years, and at least 11.5 billion people have completed nucleic acid testing.

In the eyes of ordinary people, "nucleic acid" refers to daily nucleic acid detection. Do "nucleic acid" into an industry, is this epidemic really not finished?

In fact, the relevant media missed the word "medicine" when introducing this industrial park, which triggered the speculation of the epidemic. At the end of last year, when Shanghai local media introduced this project, the abbreviations have always been "nucleic acid drug industrial park".

Before starting the construction, this plot was a well -known "bad tail building" on this plot. It has been 15 years in bad tails, so that it has become a local landmark. In December 2021, the rotten tail building was demolished and the "nucleic acid industrial park" was officially launched.

Nucleic acid testing is actually a type of nucleic acid technology application, that is, to determine whether there is a virus nucleic acid in the respiratory specimen of the patient to determine whether the new crown is infected. In fact, there are many other functions for nucleic acids for pharmaceuticals.

Nucleic acid refers to the total names of DNA and RNA. It is one of the most basic substances of life concentrated by many nucleotide monomers. In the field of biomedicine, messenger RNA (MRNA) is a disruptive drug innovation technology that will break through tumor and infectious diseases.

The mechanism of the role of nucleic acid drugs is different from traditional chemicals and biopharmaceuticals. It is the expression of differentiated or lower target genes. Diseases that have no drug treatment include genetic diseases and other difficult diseases. Therefore, the industry believes that nucleic acid drugs are expected to open the third modern new drug wave after small molecules and antibody drugs.

The nucleic acid industry has emerged in many places

Biomedical is an important pillar of Shanghai's strategic emerging industries and one of the three major pioneers in Shanghai.

According to the plan, Fengxian's nucleic acid drug industrial park has a total investment of 10 billion yuan, integrating scientific research, incubation, accelerated industrialization, and functional facilities in 2023. Meigu "Biomedical Development Belt, leading the development of the biomedical industry.

But Shanghai's movements are still slower.

In Suzhou Biomedical Industrial Park, nearly 20 nucleic acid -related innovation companies, including Aibo Biology, Santo Pharmaceutical, Ai Weixin and Gima Gene. In June last year, Yin Jianguo, president of the Industrial Park, said at the Park Merchants Forum: Nucleic acid drugs are a new direction for the future layout of the industrial park.

In addition to Suzhou City, Suzhou Kunshan County, the first top 100 county in China, is also being grabbed the business of nucleic acid. As early as 2008, Kunshan cooperated with institutions to establish small nucleic acid industry bases, and there was a saying in the industry "doing nucleic acid and getting to Kunshan". In 2015, Kunshan Biomedical Industrial Park was officially established, and the small nucleic acid industry was its main business.

Today, Shanghai has joined the competition of the nucleic acid drug industry. It is just interesting that there are currently no products such as nucleic acid drugs and nucleic acid vaccines in China.

There are not few nucleic acid drugs in the world. In addition to the well -known MRNA new crown vaccine, at least 15 small nucleic acid drugs are approved in the United States or the European Union. The main treatment of genetic disorders such as Du's muscle malnutrition is also developed for cancer treatment.

The "Research Report on the Status and Future Development of the Nucleic acid Drug Market Industry Industry and Future Development" released by Fhstrilin in May 2022 shows that nucleic acid drugs mainly include MRNA and small nucleic acids. At present, dozens of nucleic acid drugs in the world have been listed. In the short term, the future of MRNA products will mainly be various types of vaccines such as new crowns; small nucleic acid drugs can target more indications.

San Nuo Pharmaceutical, which is listed in Hong Kong stocks, is called the "first share of small nucleic acid drugs". At present, products have entered Phase II clinical. The company is established in the Suzhou Industrial Zone.

Shanghai Fengxian's "nucleic acid industrial park" is still difficult to grab the limelight of nucleic acid drugs.

### nucleic acid#

- END -